



OPIOID ABATEMENT ADVISORY COMMISSION

Kentucky Opioid Abatement Advisory Commission

Public Hearing Agenda

July 17, 2023, 9:00 a.m. ET

Administrative Office of the Courts, 1001 Vandalay Drive, Conference Room A125

Frankfort, KY 40601

View the meeting: <https://youtube.com/live/WuOpoyITuqA?feature=share>

I. CALL TO ORDER

II. INTRODUCTION

1. Bryan Hubbard, Chair and Executive Director, Kentucky Opioid Abatement Advisory Commission

III. BUSINESS MEETING SCHEDULE

1. August 8, 2023, 1:00 p.m.
 - 1024 Capital Center Drive, Suite 200, Frankfort, KY 40601
2. September 12, 2023, 1:00 p.m.
 - 1024 Capital Center Drive, Suite 200, Frankfort, KY 40601
3. September 15, 2023, 9:00 am – 3:30 pm
 - Administrative Office of the Courts, 1001 Vandalay Drive, Conference Room A125, Frankfort, KY 40601
4. October 17, 2023, 1:00 p.m.
 - 1024 Capital Center Drive, Suite 200, Frankfort, KY 40601
5. November 14, 2023, 1:00 p.m.
 - 1024 Capital Center Drive, Suite 200, Frankfort, KY 40601
6. December 12, 2023, 1:00 p.m.
 - 1024 Capital Center Drive, Suite 200, Frankfort, KY 40601

IV. EXPERT TESTIMONIES

1. Dr. Kenneth Alper, M.D. (Neuropsychiatrist) – Visiting Scientist, Nathan Kline Institute for Psychiatric Research
2. Dr. Deborah Mash, M.D., Ph.D. (Neuro Medicine/Molecular & Cellular Pharmacology) – Professor Emerita, Department of Neurology, University of Miami Miller School of Medicine
3. Dr. Srinivas (Srini) Rao, M.D., Ph.D. (Neurobiology/Neuropharmacology) – Co-Founder & Chief Scientific Officer, ATAI Life Sciences, Berlin
4. Dr. Douglas Kramer, M.D. (Pharmacovigilance & Regulatory Affairs) – Senior Vice President, Pharmacovigilance and Regulatory Affairs, Athenex, Inc.
5. Dr. Nolan Williams, M.D. (Psychiatrist, Neurologist, Behavioral Neurologist, Neuropsychiatrist) – Associate Professor, Stanford Interventional Psychiatry Clinical Research Program, Stanford University



OPIOID ABATEMENT ADVISORY COMMISSION

V. PANEL MEMBER DISCUSSION

VI. PERSONAL TESTIMONIES

1. Juliana Mulligan
2. Jessica Blackburn

VII. PUBLIC COMMENTS AND REMARKS

VIII. CLOSING REMARKS

1. Bryan Hubbard, Chair and Executive Director, Kentucky Opioid Abatement Advisory Commission

IX. ADJOURNMENT